Home/Filings/4/A/0001213900-24-035721
4/A//SEC Filing

Lowdell Mark William 4/A

Accession 0001213900-24-035721

CIK 0001711754other

Filed

Apr 23, 8:00 PM ET

Accepted

Apr 24, 2:08 PM ET

Size

8.2 KB

Accession

0001213900-24-035721

Insider Transaction Report

Form 4/AAmended
Period: 2024-04-19
Lowdell Mark William
Chief Scientific Officer
Transactions
  • Purchase

    Common Stock Warrants (right to buy)

    2024-04-19$0.13/sh+14,423$1,80314,423 total
    Exercise: $9.15From: 2024-04-24Common Stock (14,423 underlying)
  • Purchase

    Common Stock

    2024-04-19$8.32/sh+14,423$119,9991,510,806 total
Footnotes (1)
  • [F1]The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $121,802.24 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the "Termination Date") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant.

Documents

1 file

Issuer

Inmune Bio, Inc.

CIK 0001711754

Entity typeother

Related Parties

1
  • filerCIK 0001767037

Filing Metadata

Form type
4/A
Filed
Apr 23, 8:00 PM ET
Accepted
Apr 24, 2:08 PM ET
Size
8.2 KB